$243.07
2.04% day before yesterday
NYSE, Sep 06, 10:10 pm CET
ISIN
US46266C1053
Symbol
IQV

IQVIA Stock price

$243.07
+5.81 2.45% 1M
-9.90 3.91% 6M
+11.69 5.05% YTD
+24.25 11.08% 1Y
-20.15 7.66% 3Y
+89.00 57.77% 5Y
+187.11 334.36% 10Y
NYSE, Closing price Fri, Sep 06 2024
-5.07 2.04%
ISIN
US46266C1053
Symbol
IQV
Sector

Key metrics

Market capitalization $44.31b
Enterprise Value $56.08b
P/E (TTM) P/E ratio 31.52
EV/FCF (TTM) EV/FCF 30.70
EV/Sales (TTM) EV/Sales 3.70
P/S ratio (TTM) P/S ratio 2.92
P/B ratio (TTM) P/B ratio 6.60
Revenue growth (TTM) Revenue growth 3.45%
Revenue (TTM) Revenue $15.16b
EBIT (operating result TTM) EBIT $2.11b
Free Cash Flow (TTM) Free Cash Flow $1.83b
Cash position $1.68b
EPS (TTM) EPS $7.71
P/E forward 31.72
P/S forward 2.87
EV/Sales forward 3.63
Short interest 2.06%
Show more

Is IQVIA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

IQVIA Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a IQVIA forecast:

20x Buy
74%
7x Hold
26%

Analyst Opinions

27 Analysts have issued a IQVIA forecast:

Buy
74%
Hold
26%

Financial data from IQVIA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
15,162 15,162
3% 3%
100%
- Direct Costs 10,982 10,982
3% 3%
72%
4,180 4,180
5% 5%
28%
- Selling and Administrative Expenses 929 929
5% 5%
6%
- Research and Development Expense - -
-
-
3,251 3,251
9% 9%
21%
- Depreciation and Amortization 1,146 1,146
3% 3%
8%
EBIT (Operating Income) EBIT 2,105 2,105
12% 12%
14%
Net Profit 1,423 1,423
30% 30%
9%

In millions USD.

Don't miss a Thing! We will send you all news about IQVIA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IQVIA Stock News

Neutral
PRNewsWire
3 days ago
PHILADELPHIA , Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative.
Neutral
Business Wire
17 days ago
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Healthcare Conference in New York on Wednesday, September 4, 2024 at 10:00 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations webs...
Positive
Seeking Alpha
18 days ago
IQVIA Holdings Inc. stock is up following Q2 earnings, following business upsides across its portfolio. Q2 earnings showed strong performance in TAS and R&DS divisions, with a record backlog and increased guidance for FY'24. Implied valuations are corroborated at a $260/share price objective, with potential further technical upside to $283/share if momentum sustains.
More IQVIA News

Company Profile

Provides biopharmaceutical development services and commercial outsourcing services

Head office United States
CEO Ari Bousbib
Employees 87,000
Founded 1950
Website www.iqvia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today